HIV PrEP options in South Africa
-
Once-monthly oral HIV PrEP: MSD partners with Aspen for LMIC access
MSD has tapped South Africa’s Aspen to help deliver alimatravir, an investigational once‑monthly oral HIV PrEP, via royalty‑free, non‑exclusive licenses across 129 low‑ and middle‑income countries—pending trials and approvals. With 1.2m new infections in 2025 and PrEP uptake lagging, see how access could scale fast.